JPMorgan lowered the firm’s price target on Bausch + Lomb (BLCO) to $17 from $18 and keeps a Neutral rating on the shares. The firm updated its model for Q4 results and 2025 guidance and lowered its December 2025 price target on the shares. The new valuation is a slight discount to peers given the risk regarding ownership structure and interplay with Bausch Health, roughly low single-digit market CAGR within highly competitive markets, and mixed execution, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch + Lomb price target lowered to $17 from $18 at Stifel
- Bausch + Lomb Reports Robust 2024 Financial Performance and Strategic Growth
- Bausch + Lomb sees FY25 revenue $4.95B-$5.05B, consensus $5.02B
- Bausch + Lomb reports Q4 adjusted EPS 25c, consensus 23c
- Positive Outlook on Bausch + Lomb: Strategic Developments and Acquisition Drive Buy Rating